Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant urate oxidase for prevention and treatment of tumor lysis syndrome–related hyperuricemia in pediatric malignancies
CTR20242228Phase 2Active
- Sponsor
- Hangzhou Beidou Biotechnology
- Start
- Mar 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rasburicase in tumor lysis syndrome (TLS), hyperuricemia, leukemia and 4 more, sponsored by Hangzhou Beidou Biotechnology. Primary endpoint: Serum uric acid response rate. Started Mar 2026; status: active.
02
Drugs
rasburicase
03
Conditions
tumor lysis syndrome (TLS)hyperuricemialeukemialymphomaneuroblastoma
Beyond the preview
Go deeper on CTR20242228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242228.